The compounds we work with

Triple-agonist (GLP-1 / GIP / glucagon) studied for metabolic regulation.

Synthetic GHRH analog studied for visceral fat composition and IGF-1.

Modified hGH fragment (176-191) studied for lipolysis pathways.

Long-acting amylin analog studied for satiety signaling.

Oral NNMT inhibitor studied for adipocyte metabolism and lean-mass pathways.

ERR agonist studied for mitochondrial and endurance pathways.

Methionine, inositol, choline with B-complex — classic lipotropic blend.

Long-R3 variant of IGF-1 with extended half-life and reduced IGFBP binding.

Classic pulsatile GH stack — GHRH analog paired with a selective GHS-R1a agonist.

GRF(1-29) analog — a foundational GHRH peptide.

Mitochondrial-derived peptide studied for AMPK signaling and metabolic homeostasis.

Cellular cofactor for sirtuin activity and mitochondrial electron transport.

Tripeptide (Glu-Asp-Arg) studied for neuronal and pineal gland pathways.

Acetylated 28-amino-acid peptide studied for TLR signaling and innate immunity.

Blend of GHK-Cu, TB-500, BPC-157, and KPV — a four-peptide tissue and repair stack.

Tri-peptide blend: BPC-157, GHK-Cu, and TB-500 for recovery and skin research.

BPC-157 and TB-500 co-formulated for soft tissue research.

Pentadecapeptide fragment of body protection compound.

Synthetic fragment of thymosin beta-4 studied for tissue regeneration pathways.

Copper-binding tripeptide studied for fibroblast activity and skin remodeling.

Delta sleep-inducing peptide — nonapeptide studied for sleep architecture.

Heptapeptide ACTH(4-10) analog studied for BDNF pathways.

Melanocortin receptor agonist studied for neurovascular and libido pathways.

Tuftsin-derived heptapeptide studied for anxiolytic and cognitive pathways.

Cyclic melanocortin analog studied for pigmentation and appetite pathways.

Endogenous tripeptide antioxidant — the body's master redox buffer.

C-terminal α-MSH tripeptide studied for inflammatory pathway modulation.